I. Introduction
===============

Head and neck squamous cell carcinoma (HNSCC) ranks sixth among the most common neoplasms in the world and is responsible for more than 350,000 cancer deaths worldwide every year,[@B1][@B2][@B3]. In India, where tobacco is the most common etiologic factor, HNSCC is the most common cancer in men and the third most common in women, with an increasing incidence reported in young adults[@B1].

Despite an aggressive multidisciplinary approach and advances in treatment, the 5-year survival rate for HNSCC has not improved much[@B4]. Although a number of factors such as TNM stage[@B5][@B6], histologic grade of tumour[@B7][@B8], perineural invasion[@B8][@B9], depth of tumour[@B8], and extracapsular spread[@B10][@B11] have been used as prognostic markers in HNSCC, regional lymph node (LN) metastasis has been considered one of the most important factors determining treatment approach and thus long-term survival[@B8][@B10][@B11][@B12]. Even with advances in diagnostic imaging the sensitivity to detect occult LN metastasis remains limited, especially in Stages I and II[@B13][@B14]. Furthermore, it has been observed that even among patients with same stage and site of HNSCC, some patients do better than others[@B1]. The past two decades saw innovative research in a number of molecular studies on the identification of occult LN metastasis. These studies have shown that development of HNSCC is driven by multistep accumulation of genetic alterations involving various oncogenes, tumour suppressor genes, and cell adhesion molecules, resulting in a heterogeneous cell population with probable differences in invasive and metastatic behaviour and clonal proliferation of these cells[@B1][@B13][@B14][@B15][@B16][@B17]. This has led to increased interest in assessing cancer progression in HNSCC and predicting its course using different molecular markers, which has in turn fuelled the search for markers that can act as definitive prognostic/predictive markers. Furthermore, tumour heterogeneity has led to the use of multiple selected markers together with histopathology in prognostic assessment of HNSCC[@B15][@B18][@B19].

E-cadherin is a 120-kDa calcium-dependent transmembrane glycoprotein encoded by the *CDH1* tumour suppressor gene located on chromosome 16q21. It is a cell adhesion molecule that connects epithelial cells via homotypic interaction. Disruption of this interaction promotes detachment of cancer cells from their primary sites, the first step in the tumour invasion process[@B4]. Reduced or aberrant E-cadherin expression appears to be associated with various parameters such as aggressiveness of tumour, enhanced invasion, and metastatic potential in a number of malignancies including HNSCC[@B20][@B21][@B22][@B23]. The cyclin D1 gene (*CCND1*) located on chromosome 11q13 encodes a nuclear protein that is the regulatory subunit of Cdk-4 and Cdk-6. Cyclin D1 plays a major role in cell cycle transition from G1 to S phase by contributing to inactivation of the retinoblastoma (RB) gene product, and overexpression of CCND1 has been reported in 35% to 40% cases of HNSCC[@B24][@B25].

We conducted a study to assess the loss of E-cadherin (tumour suppressor gene) and overexpression of cyclin D1 (proto-oncogene) in primary tumours and metastatic nodes by immunohistochemistry (IHC) to evaluate their role as predictive markers of nodal metastasis and assess clonal expansion in HNSCC patients at our tertiary care centre.

II. Materials and Methods
=========================

1. Clinical and histopathologic characteristics
-----------------------------------------------

We selected 66 patients with HNSCC who had undergone wide local excision of primary tumour with simultaneous selective resection of regional LNs between January 2015 and December 2016, and for whom complete clinical data and surgical pathology material were available for review and IHC. HNSCC patients who underwent neoadjuvant therapies at presentation and those with distant metastasis were excluded from the study. Pathology reports and paraffin-embedded tissue blocks were retrieved from the archives and data on demographics and clinical profile including age, sex, primary tumour site, TNM stage, and histopathologic grade were collected. H&E sections of representative primary tumour were reviewed by two independent pathologists for confirmation of diagnosis and graded according to Broder\'s histologic criteria for HNSCC. TNM staging (Stage I-IVA) was performed according to American Joint Committee on Cancer (AJCC) 7th edition.

The study was approved by Institutional Ethics Committee of Armed Forces Medical College, Pune, India (approval no. pathology and allied/32/2015-17).

2. Immunohistochemistry
-----------------------

Blocks of primary site tumour covering at least 60% of the total section (in N0 cases) together with sections of the LN showing largest metastatic deposits (in case of N1-2) were selected. Sections of 3 to 4 µm thickness were cut onto coated slides for IHC using mouse monoclonal antibody against E-cadherin (clone 36 \[Biogenix, Memphis, TN, USA\]; ready to use, incubation period 30 minutes) or rabbit polyclonal antibody against cyclin D1 (clone EP12 \[PathnSitu Biotechnologies, Livermore, CA, USA\]; ready to use, incubation period 30 minutes). IHC was performed by the standard Avidin-Biotin technique according to the manufacturer\'s instructions. A section of normal mucosa and a section of tonsil were taken as positive controls for E-cadherin and cyclin D1 respectively. For negative controls, primary antibody was omitted and Tris-buffered saline was used for both markers.

3. Analysis and interpretation of staining
------------------------------------------

Intensity of membranous staining for E-cadherin[@B26] and percentage of cells showing nuclear positivity for cyclin D1[@B27] were evaluated semi-quantitatively by two independent pathologists.([Table 1](#T1){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}) All cases were classified in a binary fashion as positive or negative for each marker using a pre-decided scoring system.([Table 1](#T1){ref-type="table"}) Cytoplasmic staining was disregarded for both markers.

4. Statistical analysis
-----------------------

The IBM SPSS Statistics (ver. 20.0; IBM Co., Armonk, NY, USA) was used for statistical analysis. Association with E-cadherin and cyclin D1 was analysed for different clinicopathologic parameters. The chi-square test and the Fisher\'s exact probability test were used for comparisons of categorical data. The statistical significance was determined at *P*\<0.05 for all values.

III. Results
============

1. Clinical, demographic, and histopathologic characteristics
-------------------------------------------------------------

A total of 66 cases of HNSCC were included in the study, of which 37 cases (56.1%) had metastatic LNs and 29 cases (43.9%) were without nodal metastasis. The mean age of the study group was 57 years, with a standard deviation of 13.1 years. Most cases were in the age group of 41 to 60 (33 cases, 50.0%) and males outnumbered females. The major subsite was buccal mucosa (33 cases, 50.0%) and only one case (1.5%) involved the hard palate. Histologically, 43 cases (65.2%) were well-differentiated (low grade) and 23 cases (34.8%) were moderately differentiated or poorly differentiated HNSCC (classified as high grade). All cases were binarily classified into early (19 cases, 28.8%) or advanced stage (47 cases, 71.2%) based on TNM staging.([Table 2](#T2){ref-type="table"})

2. Patterns of IHC expression of E-cadherin and cyclin D1
---------------------------------------------------------

Expression of E-cadherin and cyclin D1 by IHC was analysed at the primary tumour site and the metastatic nodal deposit. All cases (n=66) retained expression of E-cadherin at the primary tumour site and membranous immunostaining was seen in 34 cases (51.5%), whereas E-cadherin loss was noted in 21 of 37 metastatic LNs (56.8%). Similarly, overexpression of cyclin D1 was observed in the form of nuclear positivity at the primary site tumour in 32 cases (48.5%) and in 19 of 37 metastatic nodal deposits (51.4%).([Table 3](#T3){ref-type="table"})

3. Association between E-cadherin expression and clinicopathologic indices
--------------------------------------------------------------------------

A highly significant association was observed between E-cadherin expression and LN status in HNSCC (*P*\<0.001). A significant association was also noted between E-cadherin expression and TNM stage (*P*\<0.001), indicating that loss of E-cadherin expression is associated with higher TNM stage and LN metastasis. However, there was no significant association with histologic tumour grade (*P*=0.103). In addition, a significant statistical association (*P*=0.007) was noted between expression of E-cadherin in primary tumour and expression in metastatic LN in node-positive cases (n=37).([Tables 4](#T4){ref-type="table"}, [5](#T5){ref-type="table"})

4. Association between cyclin D1 expression and clinicopathologic indices
-------------------------------------------------------------------------

A significant association was present between LN status and cyclin D1 expression (*P*=0.044) suggesting an increased rate of LN metastasis in cases with overexpression of cyclin D1. However, no significant association was noted between TNM stage and cyclin D1 expression (*P*=0.081) or between tumour grade and cyclin D1 expression (*P*=0.266). Similar to E-cadherin, there was a highly significant association (*P*\<0.001) between expression of cyclin D1 in primary tumour and expression in metastatic LN deposits in nodepositive cases (n=37).([Tables 4](#T4){ref-type="table"}, [5](#T5){ref-type="table"})

5. Correlation between E-cadherin and cyclin D1 as combination markers and clinicopathologic parameters
-------------------------------------------------------------------------------------------------------

All 66 cases were further divided into subgroups based on combined expression of E-cadherin and cyclin D1. On subgroup analysis of 37 cases with LN metastasis, the highest rate of LN metastasis was seen in the subgroup of reduced E-cadherin/cyclin D1 overexpression (negative/positive) with a rate of 43.2% (16 cases), while the lowest rate (2 cases, 5.4%) was observed in the subgroup of retained E-cadherin/low cyclin D1 expression. In contrast, among 29 cases without LN metastasis, only one (3.4%) case was in the subcategory of E-cadherin loss/cyclin D1 overexpression (negative/positive) whereas most cases (58.6%) were in the subgroup of retained E-cadherin/absent cyclin D1 (positive/negative). Thus, a significant statistical association was observed between LN metastasis and the combination of E-cadherin and cyclin D1 expression in tumour cells (*P*=0.001).([Table 6](#T6){ref-type="table"}) Similarly, a significant association was noted with TNM stage (*P*=0.001), with advanced TNM stages mostly seen in the subgroup of low E-cadherin/overexpressed cyclin D1 (17/47 cases, 36.2%).([Table 6](#T6){ref-type="table"})

IV. Discussion
==============

Traditionally, various histopathologic features such as depth of tumour[@B8], pattern of invasion[@B7][@B8], tumour differentiation, and TNM stage[@B5][@B6] have been used as predictive and prognostic markers in HNSCC. However, the lack of accurate imaging modalities to detect occult or micro-metastasis, combined with the fact that tumours showing the same TNM stage and location behave differently and a lack of consensus on management of draining LNs in TNM stage I and II, has raised serious doubts regarding the adequacy of conventional markers[@B13][@B14]. In the past two decades, extensive research has been carried out involving various biomarkers such as p53, beta-catenin, E-cadherin, and cyclin D1 to search for a definitive predictive and prognostic biomarker in HNSCC[@B18][@B19]. We studied the importance of E-cadherin and cyclin D1 as combination markers in terms of their relationship to clinicopathologic parameters to examine their role as predictive markers in HNSCC and also examined their expression in metastatic LNs for assessment of clonal proliferation.

The mean age of the study group was 57 years with a standard deviation of 13.1 years, which is similar to the study of Do et al.[@B28] in which the mean age of patients was 61.6 years with no case under 25 years of age and the male:female ratio was 130:16. Loss of E-cadherin expression in primary site tumour (irrespective of comparison of nodal status) was seen in 48.48% cases and cyclin D1 overexpression was observed in 48.45% cases, compared with rates of 77% and 69%, respectively, reported by Do et al.[@B28] and 50.7% and 29.3% reported by Ahmed et al.[@B29]. Furthermore, a review of literature revealed great variance in values, ranging from 29.3% to 69%. This variation might be due to different scoring systems used in evaluations, such as the cutoff for cyclin D1 overexpression ranging from 5% to 50% cells. The choice of cutoff values for various markers in HNSCC to distinguish positive from negative results usually lacks a fundamental basis and is rather arbitrary[@B30].

In our study, 29 cases (78.4%) with nodal metastasis showed loss of E-cadherin expression while 26 cases (89.7%) without metastatic nodes showed retained E-cadherin expression ([Table 4](#T4){ref-type="table"}); this indicates that E-cadherin loss is significantly higher in cases with LN metastasis and is in agreement with various other studies[@B28][@B29][@B30][@B31][@B32]. Akhtar et al.[@B33] and Kaur et al.[@B34] reported loss of E-cadherin in 5/6 and 7/10 cases (respectively), including cases with LN metastasis. Their results differ from those of Balasundaram et al.[@B35], Wang et al.[@B36], Mattijssen et al.[@B37], and Mehendiratta et al.[@B1], who reported prognostic significance of E-cadherin in HNSCC cases. Regarding tumour differentiation, which is considered to be an independent prognostic marker, we did not find any significant association between tumour grade and E-cadherin expression in our study, which is in concordance with results of several past studies[@B28][@B30][@B38][@B39] but differs from some other studies[@B29][@B33][@B34]. This discrepancy may be due to subjective variation in grading the tumour, a limitation of Broder\'s system of grading HNSCCs, as a number of stage IV tumours in our study were graded as well differentiated. Also, loss of E-cadherin was significantly higher in advanced TNM stages III and IVA, similar to a report by Ahmed et al.[@B29] involving only laryngeal SCCs. In our study, 94.7% of early-stage cases showed normal expression of E-cadherin whereas only 34% of advanced-stage cases retained E-cadherin expression. However, this finding differs from most previous studies, which have not reported any significant association between E-cadherin expression and TNM stage[@B28][@B30][@B35].

Cyclin D1 overexpression was also found to be significantly associated with LN metastasis.([Table 4](#T4){ref-type="table"}) These results are comparable to a number of previous studies including those of Do et al.[@B28], Ahmed et al.[@B29], Carlos de Vicente et al.[@B40] and a few Indian studies[@B31][@B41][@B42], but in discordance with studies by Michalides et al.[@B43] and Takes et al.[@B30]. Regarding TNM stage, few studies in the literature have reported a significant association between TNM stage and cyclin D1 expression[@B28][@B29][@B44]. In our study we did not find a statistically significant association (*P*=0.081) although we noted that 68.4% of early-stage tumours did not show cyclin D1 overexpression. No significant association was noted with tumour grade, which is in agreement with previous studies[@B28][@B42], although there are a few reports of a significant correlation between tumour grade and cyclin D1 overexpression[@B29][@B41][@B44][@B45][@B46].

Furthermore, among 37 cases with nodal metastasis, 29 showed loss of E-cadherin at the primary tumour site of which 21 cases (72.4%) also had loss of E-cadherin at secondary nodal deposits.([Table 5](#T5){ref-type="table"}) This statistically significant association (*P*=0.007) indicates that the sub-clone of tumour cells that had lost E-cadherin expression proliferated and metastasized to the draining LNs. This is the first report of this finding in HNSCCs. However, 8 cases (27.6%) were negative at the primary site but showed positive E-cadherin expression in the LN deposit. In addition, out of 8 cases with LN metastasis that retained E-cadherin expression at primary site, 7 cases (87.5%) retained E-cadherin expression in the nodal deposit and one case (12.5%) showed loss at the secondary site. These cases point toward heterogeneity of the tumour cells, possibly reflecting additional mutations that play a role in carcinogenesis. Also, a highly significant association (*P*\<0.001) was noted between cyclin D1 overexpression at the primary site tumour and at secondary metastatic deposits in node-positive cases, again pointing to clonal expansion. Similar results suggesting tumour heterogeneity were noted with cyclin D1 expression.([Table 5](#T5){ref-type="table"})

The subgroup of cases with loss of E-cadherin/overexpression of cyclin D1 (negative/positive) showed the highest rate of LN metastasis and higher TNM stages (*P*\<0.001).([Table 6](#T6){ref-type="table"}) However, 37.9% of the LN-negative group and 51.4% of the LN-positive group showed both markers as either negative or positive, signifying interplay between additional mutations and these markers.

These results imply that overexpression of cyclin D1 as a cell proliferation marker together with loss of the cell adhesion molecule E-cadherin plays a significant role in metastasis with each marker probably influencing the genesis of mutations in other genes. The combination of these markers might help to predict aggressive disease and prognosis in HNSCC.

V. Conclusion
=============

E-cadherin and cyclin D1 are potential predictive markers of LN metastasis. The combination of these two markers might help identify early-stage HNSCCs at higher risk of LN metastasis, although tumour heterogeneity may interfere with the association in some cases. With emerging evidence of definite roles of different biomarkers in various malignancies, more randomized trials and meta-analysis studies are required to identify the optimal prognostic and predictive markers for HNSCCs.
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###### Scoring of E-cadherin and cyclin D1 immunostaining[@B26][@B27]

![](jkaoms-44-182-i001)

  Grading   E-cadherin expression, intensity of membranous immunostaining   Cyclin D1 expression, nuclear staining positive cell (%)
  --------- --------------------------------------------------------------- ----------------------------------------------------------
  0         Negative^1^                                                     No cells^1^
  1+        Weak^1^                                                         1--25^1^
  2+        Moderate^2^                                                     26--50^1^
  3+        Strong^2^                                                       51--75^2^
  4+                                                                        76--100^2^

Binary classification: ^1^loss, ^2^positive.

###### Population characteristics of 66 patients with head and neck squamous cell carcinoma

![](jkaoms-44-182-i002)

  Characteristic                     No. of cases (%)
  ---------------------------------- ------------------
  Total no. of cases                 66 (100)
  Gender                             
   Male                              56 (84.8)
   Female                            10 (15.2)
  Age group (yr)                     
   \<40                              7 (10.6)
   41--60                            33 (50.0)
   \>61                              26 (39.4)
  Site                               
   Buccal mucosa                     33 (50.0)
   Alveolus                          20 (30.3)
   Tongue                            6 (9.1)
   Larynx                            4 (6.1)
   Lip                               2 (3.0)
   Hard palate                       1 (1.5)
  Histologic tumour grade            
   Low grade (well differentiated)   43 (65.2)
   High grade                        23 (34.8)
    Moderately differentiated        20 (30.3)
    Poorly differentiated            3 (4.5)
  TNM stage                          
   Early (I+II)                      19 (28.8)
    I                                5 (7.6)
    II                               14 (21.2)
   Advanced (III+IVA)                47 (71.2)
    III                              10 (15.2)
    IVA                              37 (56.1)
  Lymph node metastasis              
   Negative (N0)                     29 (43.9)
   Positive (N1-2)                   37 (56.1)

###### Expression of E-cadherin and cyclin D1 by immunohistochemical staining

![](jkaoms-44-182-i003)

                            E-cadherin staining   Cyclin D1 staining   Total                   
  ------------------------- --------------------- -------------------- ----------- ----------- ----
  Primary tumour            32 (48.5)             34 (51.5)            34 (51.5)   32 (48.5)   66
  Metastatic node deposit   21 (56.8)             16 (43.2)            18 (48.6)   19 (51.4)   37

Values are presented as number (%) or number only.

###### Clinicopathological associations with E-cadherin and cyclin D1 in HNSCC

![](jkaoms-44-182-i004)

  Characteristic          No. of cases (%)   E-cadherin (n=66)   Cyclin D1 (n=66)   *P*-value                           
  ----------------------- ------------------ ------------------- ------------------ ----------- ----------- ----------- -------
  Lymph node metastasis                                                                                                 
   Negative (N0)          29 (43.9)          3 (10.3)            26 (89.7)          \<0.001     19 (65.5)   10 (34.5)   0.044
   Positive (N1-2)        37 (56.1)          29 (78.4)           8 (21.6)                       15 (40.5)   22 (59.5)   
  TNM stage                                                                                                             
   Early (I+II)           19 (28.8)          1 (5.3)             18 (94.7)          \<0.001     13 (68.4)   6 (31.6)    0.081
   Advanced (III+IVA)     47 (71.2)          31 (66.0)           16 (34.0)                      21 (44.7)   26 (55.3)   
  Tumour grade                                                                                                          
   Low grade              43 (65.2)          24 (55.8)           29 (67.4)          0.103       20 (46.5)   23 (53.3)   0.266
   High grade             23 (34.8)          8 (34.8)            15 (65.2)                      14 (60.9)   9 (39.1)    

Values are presented as number (%).

###### Association between expression of E-cadherin and cyclin D1 at primary tumour site and at metastatic nodal deposit in node-positive (N1-2) cases (n=37)

![](jkaoms-44-182-i005)

  Primary site            No. of cases (%)   Metastatic lymph node deposit   *P*-value             
  ----------------------- ------------------ ------------------------------- --------------------- ---------
  E-cadherin expression                      Loss of expression              Retained expression   0.007
   Loss of expression     29 (78.4)          21 (72.4)                       8 (27.6)              
   Retained expression    8 (21.6)           1 (12.5)                        7 (87.5)              
  Cyclin D1 expression                       Not overexpressed               Overexpressed         \<0.001
   Not overexpressed      15 (40.5)          14 (93.3)                       1 (6.7)               
   Overexpressed          22 (59.5)          4 (18.2)                        18 (81.8)             

Values are presented as number (%).

###### Association between E-cadherin and cyclin D1 as combination markers and clinicopathologic parameters (n=66)

![](jkaoms-44-182-i006)

                          No. of cases (%)   Subgroups in primary tumour (E-cadherin/cyclin D1)   *P*-value                          
  ----------------------- ------------------ ---------------------------------------------------- ----------- ---------- ----------- ---------
  Lymph node metastasis                                                                                                              
   Negative (N0)          29 (43.9)          17 (58.6)                                            2 (6.9)     9 (31.0)   1 (3.4)     \<0.001
   Positive (N1-2)        37 (56.1)          2 (5.4)                                              13 (35.1)   6 (16.2)   16 (43.2)   
  TNM stage                                                                                                                          
   Early (I+II)           19 (28.8)          12 (63.2)                                            1 (5.3)     6 (31.6)   0 (0)       0.001
   Advanced (III+IVA)     47 (71.2)          7 (14.9)                                             14 (29.8)   9 (19.1)   17 (36.2)   

Values are presented as number (%).
